Take your PAH and
CTEPH patients farther
with Adempas
In pulmonary arterial hypertension (PAH),
(WHO Group 1)
36m
improvement (mean) in 6-minute
walk distance (6MWD) over placebo
at Week 12 (95% Confidence Interval
(CI): 20m-52m; p<0.0001)
In inoperable and persistent/recurrent chronic
thromboembolic hypertension (CTEPH), (WHO Group 4)
46m
improvement (mean) in
6MWD over placebo at Week 16
(95% CI: 25m-67m; p<0.0001)
Randomized, multicenter, placebo-controlled clinical study of
443 adult PAH patients with predominantly WHO Functional
Class II-III. The primary endpoint was change from baseline
in 6MWD at 12 weeks.
Randomized, multicenter, placebo-controlled clinical study of
261 adult patients with persistent/recurrent CTEPH
after surgery or who were inoperable. The primary
endpoint was change from baseline in 6MWD at
16 weeks.
CONTRAINDICATIONS (continued)
Bleeding. In the placebo-controlled clinical trials, serious bleeding
occurred in 2.4% of patients taking Adempas compared to 0% of
placebo patients. Serious hemoptysis occurred in 5 (1%) patients
taking Adempas compared to 0 placebo patients, including
one event with fatal outcome. Serious hemorrhagic events also
included 2 patients with vaginal hemorrhage, 2 with catheter site
hemorrhage, and 1 each with subdural hematoma, hematemesis,
and intra-abdominal hemorrhage.
WARNINGS AND PRECAUTIONS
Embryo-Fetal Toxicity. Adem 2